Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19
Background: Different biomarkers have been suggested as novel biomarkers of coronavirus disease 2019 (COVID-19) theragnosis. With the aim of having a better clinical management of COVID-19, we decided to determine the relationship between hematological, inflammatory, and novel biomarkers with severe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023101046 |
| _version_ | 1797383914962026496 |
|---|---|
| author | Sanaz Rezaeian Fatemeh Razmjooei Masoome Pourmokhtari Amir Abdoli Mirza Ali Mofazzal Jahromi Kambiz Bagheri |
| author_facet | Sanaz Rezaeian Fatemeh Razmjooei Masoome Pourmokhtari Amir Abdoli Mirza Ali Mofazzal Jahromi Kambiz Bagheri |
| author_sort | Sanaz Rezaeian |
| collection | DOAJ |
| description | Background: Different biomarkers have been suggested as novel biomarkers of coronavirus disease 2019 (COVID-19) theragnosis. With the aim of having a better clinical management of COVID-19, we decided to determine the relationship between hematological, inflammatory, and novel biomarkers with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin (Ig)M and IgG antibodies. Methods: Blood samples from 127 confirmed COVID-19 patients aged 11–84 years old were collected and tested for SARS-CoV-2 IgM and IgG antibodies alongside with hematological, inflammatory, and novel biomarkers. The Spearman correlation test was utilized to analyze the correlation between these biomarkers with SARS-CoV-2 IgM and IgG antibodies. Results: The SARS-CoV-2 IgM antibody significantly correlated with erythrocyte sedimentation rate (ESR) (r = 0.329, p = 0.000), C-reactive protein (CRP) (r = 0.459, p = 0.000), interleukin (IL)-6 (r = 0.345, p = 0.000), IL-8 (r = 0.263, p = 0.003), neutrophil to lymphocyte ratio (NLR) (r = 0.182, p = 0.040), derived NLR (dNLR) (r = 0.197, p = 0.026), neutrophil to monocyte ratio (NMR) (r = 0.184, p = 0.038), and CRP to lymphocyte ratio (CLR) (r = 0.495, p = 0.000). Also, we find significant correlation between SARS-CoV-2 IgG antibody with hemoglobin (Hb) (r = −0.257, p = 0.004), hematocrit (Hct) (r = −0.227, p = 0.010), mean corpuscular Hb concentration (MCHC) (r = −0.212, p = 0.017), lymphocyte count (r = −0.211, p = 0.017), platelet count (r = 0.179, p = 0.044), ESR (r = 0.461, p = 0.000), CRP (r = 0.344, p = 0.000), IL-6 (r = 0.178, p = 0.046), IL-8 (r = 0.237, p = 0.007), platelet to lymphocyte ratio (PLR) (r = 0.295, p = 0.001), and CLR (r = 0.376, p = 0.000). Conclusion: Hematological biomarkers (Hb, Hct, MCHC, lymphocyte count, and platelet count), inflammatory biomarkers (ESR, CRP, IL-6, and IL-8), and novel biomarkers (dNLR, NLR, NMR, PLR, and CLR) are valuable indicators for clinical management of COVID-19. |
| first_indexed | 2024-03-08T21:27:56Z |
| format | Article |
| id | doaj.art-2ab3914c65c941f69ed81d056cf3e8c0 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T21:27:56Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-2ab3914c65c941f69ed81d056cf3e8c02023-12-21T07:35:03ZengElsevierHeliyon2405-84402023-12-01912e22896Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19Sanaz Rezaeian0Fatemeh Razmjooei1Masoome Pourmokhtari2Amir Abdoli3Mirza Ali Mofazzal Jahromi4Kambiz Bagheri5Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran; Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, IranStudent Research Committee, Jahrom University of Medical Sciences, Jahrom, IranDepartment of Orthopedics, School of Medicine, Jahrom University of Medical Sciences, Jahrom, IranZoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran; Department of Parasitology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, IranZoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran; Department of Immunology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran; Department of Advanced Medical Sciences & Technologies, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran; Corresponding author. Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran.Department of Immunology, Faculty of Medicine, Kazerun Branch, Islamic Azad University, Kazerun, Iran; Corresponding author.Background: Different biomarkers have been suggested as novel biomarkers of coronavirus disease 2019 (COVID-19) theragnosis. With the aim of having a better clinical management of COVID-19, we decided to determine the relationship between hematological, inflammatory, and novel biomarkers with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin (Ig)M and IgG antibodies. Methods: Blood samples from 127 confirmed COVID-19 patients aged 11–84 years old were collected and tested for SARS-CoV-2 IgM and IgG antibodies alongside with hematological, inflammatory, and novel biomarkers. The Spearman correlation test was utilized to analyze the correlation between these biomarkers with SARS-CoV-2 IgM and IgG antibodies. Results: The SARS-CoV-2 IgM antibody significantly correlated with erythrocyte sedimentation rate (ESR) (r = 0.329, p = 0.000), C-reactive protein (CRP) (r = 0.459, p = 0.000), interleukin (IL)-6 (r = 0.345, p = 0.000), IL-8 (r = 0.263, p = 0.003), neutrophil to lymphocyte ratio (NLR) (r = 0.182, p = 0.040), derived NLR (dNLR) (r = 0.197, p = 0.026), neutrophil to monocyte ratio (NMR) (r = 0.184, p = 0.038), and CRP to lymphocyte ratio (CLR) (r = 0.495, p = 0.000). Also, we find significant correlation between SARS-CoV-2 IgG antibody with hemoglobin (Hb) (r = −0.257, p = 0.004), hematocrit (Hct) (r = −0.227, p = 0.010), mean corpuscular Hb concentration (MCHC) (r = −0.212, p = 0.017), lymphocyte count (r = −0.211, p = 0.017), platelet count (r = 0.179, p = 0.044), ESR (r = 0.461, p = 0.000), CRP (r = 0.344, p = 0.000), IL-6 (r = 0.178, p = 0.046), IL-8 (r = 0.237, p = 0.007), platelet to lymphocyte ratio (PLR) (r = 0.295, p = 0.001), and CLR (r = 0.376, p = 0.000). Conclusion: Hematological biomarkers (Hb, Hct, MCHC, lymphocyte count, and platelet count), inflammatory biomarkers (ESR, CRP, IL-6, and IL-8), and novel biomarkers (dNLR, NLR, NMR, PLR, and CLR) are valuable indicators for clinical management of COVID-19.http://www.sciencedirect.com/science/article/pii/S2405844023101046COVID-19SARS-CoV-2Hematological biomarkersInflammatory biomarkersNovel biomarkers |
| spellingShingle | Sanaz Rezaeian Fatemeh Razmjooei Masoome Pourmokhtari Amir Abdoli Mirza Ali Mofazzal Jahromi Kambiz Bagheri Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19 Heliyon COVID-19 SARS-CoV-2 Hematological biomarkers Inflammatory biomarkers Novel biomarkers |
| title | Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19 |
| title_full | Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19 |
| title_fullStr | Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19 |
| title_full_unstemmed | Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19 |
| title_short | Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19 |
| title_sort | hematological inflammatory and novel biomarkers assessment as an eminent strategy for clinical management of covid 19 |
| topic | COVID-19 SARS-CoV-2 Hematological biomarkers Inflammatory biomarkers Novel biomarkers |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023101046 |
| work_keys_str_mv | AT sanazrezaeian hematologicalinflammatoryandnovelbiomarkersassessmentasaneminentstrategyforclinicalmanagementofcovid19 AT fatemehrazmjooei hematologicalinflammatoryandnovelbiomarkersassessmentasaneminentstrategyforclinicalmanagementofcovid19 AT masoomepourmokhtari hematologicalinflammatoryandnovelbiomarkersassessmentasaneminentstrategyforclinicalmanagementofcovid19 AT amirabdoli hematologicalinflammatoryandnovelbiomarkersassessmentasaneminentstrategyforclinicalmanagementofcovid19 AT mirzaalimofazzaljahromi hematologicalinflammatoryandnovelbiomarkersassessmentasaneminentstrategyforclinicalmanagementofcovid19 AT kambizbagheri hematologicalinflammatoryandnovelbiomarkersassessmentasaneminentstrategyforclinicalmanagementofcovid19 |